[203Pb] VMT 01 - Perspective Therapeutics
Alternative Names: [203Pb]-VMT-01Latest Information Update: 19 Jul 2023
At a glance
- Originator Viewpoint Molecular Targeting
- Developer Perspective Therapeutics
- Class Antineoplastics; Imaging agents; Peptides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Radionuclide imaging enhancers; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Malignant melanoma
Most Recent Events
- 01 Jun 2023 Phase-I/II clinical trials in Malignant melanoma (Diagnosis) in USA (IV) (NCT05655312)
- 14 Apr 2023 Efficacy data from a phase I TIMAR1 trial presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 24 Feb 2022 [203Pb] VMT 01 - Viewpoint Molecular Targeting is available for licensing as of 24 Feb 2022. https://viewpointmt.com/about/partners/